MedTrace Logo

Computation Prediction of Drug Response Based on Omics Data

NCT05833802 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2023-04-27

No results posted yet for this study

Summary

The goal of this observational study is to assess the performance of computational medicine technology in predicting patients response to anticancer drugs based on omics data.The main question it aims to answer is test consistency between the computing drug response and the response of real-world clinical trials. Participants will take part in silico.

Conditions

Interventions

OTHER

virtual anti-cancer drug

the virtual anti-cancer drug was formulation generated by computer modeling and artificial intelligence technology

Sponsors & Collaborators

  • Beijing Phil Rivers Technology

    collaborator UNKNOWN

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Min Jiang · Peking University Cancer Hospital & Institute

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2024-05-15
Completion
2024-09-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05833802 on ClinicalTrials.gov